Precision Immuno-Oncology: Prospects of Individualized Immunotherapy for Pancreatic Cancer

Precision Immuno-Oncology: Prospects of Individualized Immunotherapy for Pancreatic Cancer

Pancreatic cancer, most commonly referring to pancreatic ductal adenocarcinoma (PDAC), remains one of the most deadly diseases, with very few effective therapies available. Emerging as a new modality of modern cancer treatments, immunotherapy has shown promises for various cancer types. Over the pas...

Full description

Bibliographic Details
Main Authors:	Jiajia Zhang, Christopher L. Wolfgang, Lei Zheng
Format:	Article
Language:	English
Published:	MDPI AG 2018-01-01
Series:	Cancers
Subjects:	pancreatic cancer pancreatic ductal adenocarcinoma precision medicine immunotherapy immune checkpoint vaccine tumor microenvironment
Online Access:	http://www.mdpi.com/2072-6694/10/2/39

Similar Items

Epigenetic modulation enhances immunotherapy for pancreatic ductal adenocarcinoma
by: Yan Li, et al.
Published: (2022-01-01)

Molecular Subtyping and Precision Medicine for Pancreatic Cancer
by: Fieke E. M. Froeling, et al.
Published: (2021-01-01)

The Prospect of Harnessing the Microbiome to Improve Immunotherapeutic Response in Pancreatic Cancer
by: Sherise Rogers, et al.
Published: (2023-12-01)

A Comparison of Spatial and Phenotypic Immune Profiles of Pancreatic Ductal Adenocarcinoma and Its Precursor Lesions
by: Thomas Enzler, et al.
Published: (2024-03-01)

Unveiling the immunosuppressive landscape of pancreatic ductal adenocarcinoma: implications for innovative immunotherapy strategies
by: Songyu Guo, et al.
Published: (2024-03-01)

Inflammation, Biomarkers and Immuno-Oncology Pathways in Pancreatic Cancer
by: Belinda Lee, et al.
Published: (2019-04-01)

Advances in Pancreatic Ductal Adenocarcinoma Treatment
by: Eric M. Anderson, et al.
Published: (2021-11-01)

Nanoparticle-Based Therapeutic Strategies for Enhanced Pancreatic Ductal Adenocarcinoma Immunotherapy
by: Wanting Hou, et al.
Published: (2022-09-01)

Radiation combines with immune checkpoint blockade to enhance T cell priming in a murine model of poorly immunogenic pancreatic cancer
by: Courtney T. Stump, et al.
Published: (2021-11-01)

Targeting the Cancer–Neuronal Crosstalk in the Pancreatic Cancer Microenvironment
by: Ylenia Capodanno, et al.
Published: (2023-10-01)

B7 Family Members in Pancreatic Ductal Adenocarcinoma: Attractive Targets for Cancer Immunotherapy
by: Xin Chen, et al.
Published: (2022-11-01)

Overcoming the Fibrotic Fortress in Pancreatic Ductal Adenocarcinoma: Challenges and Opportunities
by: Kay K. Myo Min, et al.
Published: (2023-04-01)

Integrated analysis of senescence-associated genes in pancreatic ductal adenocarcinoma
by: Zhi-gang Zhu, et al.
Published: (2022-08-01)

Exploring the Biology of Cancer-Associated Fibroblasts in Pancreatic Cancer
by: Adam S. Bryce, et al.
Published: (2022-10-01)

Tumor-Associated Macrophages in Pancreatic Ductal Adenocarcinoma: Therapeutic Opportunities and Clinical Challenges
by: Ashleigh R. Poh, et al.
Published: (2021-06-01)

The Role of Neural Signaling in the Pancreatic Cancer Microenvironment
by: Ryota Takahashi, et al.
Published: (2022-08-01)

Dynamic profiling of immune microenvironment during pancreatic cancer development suggests early intervention and combination strategy of immunotherapy
by: Jiaqi Yang, et al.
Published: (2022-04-01)

Pancreatic ductal adenocarcinoma arising from the pancreatic parenchyma compressed by a huge pancreatic lipoma: a case report
by: Seiji Nakahara, et al.
Published: (2023-08-01)

Recent advances in precision medicine for pancreatic ductal adenocarcinoma
by: Hiromitsu Hayashi, et al.
Published: (2021-07-01)

The immune escape signature predicts the prognosis and immunotherapy sensitivity for pancreatic ductal adenocarcinoma
by: Hao Lu, et al.
Published: (2022-09-01)

Development and Verification of the Hypoxia- and Immune-Associated Prognostic Signature for Pancreatic Ductal Adenocarcinoma
by: Dongjie Chen, et al.
Published: (2021-10-01)

The impact of immunotherapy on the survival of pancreatic adenocarcinoma patients who do not receive definitive surgery of the tumor
by: Saber Amin, et al.
Published: (2020-09-01)

High hypoxia status in pancreatic cancer is associated with multiple hallmarks of an immunosuppressive tumor microenvironment
by: Hassan Sadozai, et al.
Published: (2024-03-01)

Pancreatic tail cancer in the setting of pancreatitis with a review of the literature: A case report
by: Shinji Rho, et al.
Published: (2023-10-01)

Genetic Redirection of T Cells for the Treatment of Pancreatic Cancer
by: Aesha I. Ali, et al.
Published: (2019-02-01)

Pancreatic Ductal Adenocarcinoma: A Strong Imbalance of Good and Bad Immunological Cops in the Tumor Microenvironment
by: Etienne D. Foucher, et al.
Published: (2018-05-01)

Cold Atmospheric Plasma Treatment for Pancreatic Cancer–The Importance of Pancreatic Stellate Cells
by: Ruben Verloy, et al.
Published: (2020-09-01)

Advances in Immunotherapeutics in Pancreatic Ductal Adenocarcinoma
by: Tarak Chouari, et al.
Published: (2023-08-01)

Clinical features and images of malignant lymphoma localized in the pancreatic head to differentiate from pancreatic ductal adenocarcinoma: a case series study
by: Naohiro Kato, et al.
Published: (2023-05-01)

Pancreatic Cancer Organoids in the Field of Precision Medicine: A Review of Literature and Experience on Drug Sensitivity Testing with Multiple Readouts and Synergy Scoring
by: Lotta Mäkinen, et al.
Published: (2022-01-01)

Translational Learnings in the Development of Chemo-Immunotherapy Combination to Bypass the Cold Tumor Microenvironment in Pancreatic Ductal Adenocarcinoma
by: Hélène Kaplon
Published: (2022-05-01)

The Desmoplastic Stroma of Pancreatic Cancer: Multilayered Levels of Heterogeneity, Clinical Significance, and Therapeutic Opportunities
by: Yohei Masugi
Published: (2022-07-01)

Differentiating benign from malignant pancreatic cysts on computed tomography
by: Rajesh Kumar Yadav, et al.
Published: (2020-01-01)

Clinical Evaluation of the Pancreatic Cancer Microenvironment: Opportunities and Challenges
by: Julianne M. Szczepanski, et al.
Published: (2024-02-01)

A feasible CT feature to differentiate focal‐type autoimmune pancreatitis from pancreatic ductal adenocarcinoma
by: Chaobin He, et al.
Published: (2019-10-01)

Association of Neutrophil, Platelet, and Lymphocyte Ratios with the Prognosis in Unresectable and Metastatic Pancreatic Cancer
by: Jessica Allen, et al.
Published: (2020-10-01)

Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma
by: Jia-qiao Fan, et al.
Published: (2020-02-01)

Nanoparticle-based immunotherapy of pancreatic cancer
by: Gaetan Aime Noubissi Nzeteu, et al.
Published: (2022-08-01)

Disparities in Pancreatic Ductal Adenocarcinoma—The Significance of Hispanic Ethnicity, Subgroup Analysis, and Treatment Facility on Clinical Outcomes
by: Andrea N. Riner, et al.
Published: (2020-06-01)

Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options
by: Derya Kabacaoglu, et al.
Published: (2018-08-01)